Medical Device Procurement in South Korea: A Supplier's Guide [2026]

South Korea is one of Asia's most advanced medical device markets, with a universal health insurance system, world-class hospitals, and strong government investment in healthcare innovation. The market is valued at approximately USD 8 billion, with high adoption rates for advanced technologies. For foreign suppliers, Korea offers a sophisticated buyer base but requires navigating MFDS regulatory requirements and the HIRA reimbursement system.

Regulatory authority and approval pathway

The Ministry of Food and Drug Safety (MFDS) regulates medical devices under the Medical Devices Act:

• Device classification: Korea uses a four-class system (Class I-IV) similar to international frameworks.
• Pre-market approval: Class II-IV devices require MFDS technical review and approval. Class III-IV devices undergo full technical documentation review including clinical data assessment.
• KGMP (Korea Good Manufacturing Practice): All manufacturers must demonstrate GMP compliance. MFDS conducts facility audits — for foreign manufacturers, this means MFDS auditors visiting your manufacturing site or accepting third-party audit reports under mutual recognition agreements.
• Korean Testing: Certain device categories require testing at MFDS-designated Korean testing laboratories, even if equivalent international test reports exist.
• In-Country Caretaker (ICC): Foreign manufacturers must appoint a Korean-based ICC or licensed importer who holds regulatory responsibility.

Korea participates in the IMDRF and has mutual recognition arrangements with several regulators, though these do not eliminate the need for Korean-specific submissions.

Key procurement platforms and channels

• KONEPS (Korea ON-line E-Procurement System): The primary public procurement portal operated by the Public Procurement Service. National and public hospital tenders are published here.
• HIRA (Health Insurance Review and Assessment Service): Devices must receive HIRA reimbursement codes and pricing to be purchased by hospitals under the National Health Insurance (NHI) system. HIRA pricing negotiations directly determine commercial viability.
• Hospital group procurement: Large hospital networks (Samsung Medical Center, Asan Medical Center, Seoul National University Hospital) conduct their own procurement for high-value devices.
• Distributor channels: Korean distributors with established hospital relationships are essential for market access, particularly outside Seoul.

Compliance requirements for tenders

• Korean-language submissions: All regulatory filings, tender responses, and labeling must be in Korean.
• KS standards: Compliance with Korean Industrial Standards (KS) may be required for certain device categories.
• Clinical evidence: MFDS may require Korean clinical data for higher-risk devices, particularly if the Korean patient population differs from the study population.
• Post-market requirements: Re-evaluation reviews and adverse event reporting to MFDS are mandatory.

Market size and opportunity

Korea's medical device market is growing at 7-8% annually, driven by:

• Aging population: Korea's population is aging faster than any other OECD country, driving demand for chronic disease management devices.
• Medical tourism: Korea's medical tourism industry drives hospital investment in premium equipment.
• Digital health leadership: Government initiatives in AI diagnostics, telemedicine, and connected health create new procurement categories.
• Export manufacturing: Korea is both a consumer and major manufacturer of medical devices, creating partnership opportunities.

Tips for foreign suppliers

1. Engage HIRA early: Reimbursement pricing determines your market viability. Start HIRA engagement during the MFDS approval process, not after.
2. Prepare for KGMP audits: MFDS facility audits are thorough. Ensure your manufacturing site is audit-ready before submitting your application.
3. Select a strong Korean partner: Your ICC/importer is your regulatory and commercial lifeline. Choose a partner with MFDS experience and hospital access.
4. Invest in Korean clinical data: Korean clinicians and regulators value local clinical evidence. Consider Korean investigational sites in your clinical development plan.
5. Use tender automation: MedStrato monitors Korean procurement opportunities across KONEPS and hospital networks. Book a demo to see how.